

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Hemostemix Inc. (“**Hemostemix**” or the “**Company**”)
Suite 1150, 707-7th Avenue SW
Calgary, Alberta, T2P 3H6

Item 2 Date of Material Change

May 9, 2022

Item 3 News Release

The news release was disseminated on May 10, 2022 through Stockwatch.

Item 4 Summary of Material Change

Hemostemix announced the return of its intellectual property and the settlement of all lawsuits with Aspire Health Science, LLC.

Item 5.1 Full Description of Material Change

Hemostemix Inc. (“**Hemostemix**” or the “**Company**”) (TSXV: HEM; OTC: HMTXF) is pleased to announce it has settled all litigation with, and closed the settlement agreement with, Aspire Health Science, LLC., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald Cooper, and Kingsman Scientific Management. Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trial data, all historical data from Hemostemix Israel, and the randomization tables that are required to analyse the North American and South African ACP-01 clinical trial data.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Item 5.2 Disclosure for Restructuring Transactions

Not Applicable

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not Applicable

Item 7 Omitted Information

No significant facts remain confidential in, or no information has been omitted from, this report.

Item 8 Executive Officer

For more information, please contact Thomas Smeenk, President
Telephone: (905) 580-4170

Item 9 Date of report:

May 10, 2022